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Abstract
Background: Several studies have shown overexpression of leptin in microarray experiments in pre-eclampsia (PE)
and in hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome. We decided to study four leptin receptor
(LEPR) SNP polymorphisms in HELLP syndrome patients by using quantitative real-time PCR and melting curve
analysis.
Methods: DNA was isolated from blood samples from 83 normotensive pregnant women and 75 HELLP syndrome
patients. Four SNPs, LEPR c.326A>G (K109), LEPR c.668A>G (Q223R), LEPR c.1968G>C (K656N) and LEPR c.3024A>G
(S1008) were determined by quantitative real-time PCR and melting curve analysis. Investigators were blinded to
clinical outcomes.
Results: LEPR c.326A>G, LEPR c.668A>G, LEPR c.1968G>C and LEPR c.3024A>G allele, genotype and haplotype
polymorphisms were not different in HELLP syndrome patients and normotensive healthy pregnants. There were
strong linkage disequilibrium (LD) between loci c.326A>G and c.6687A>G (D’ = 0.974), and c.668A>G and c.1968G>C
(D’ = 0.934), and c.326A>G and c.1968G>C (D’ = 0.885), and c.1968G>C and c.3024A>G (D’ = 1.0). However, linkages
of c.3024A>G with c.668A>G (D’ = 0.111) and c.326A>G (D’ = 0.398) were weak. The Hardy-Weinberg equilibrium
was observed for all polymorphisms. However the LEPR c.326A>G AG genotype was twice more frequent and the
(AG AG GG AG) haplotype was three times more frequent in HELLP syndrome patients. The introduced quantitative
real-time PCR combined with melting curve analysis is a fast and reliable method for the determination of LEPR
SNPs.
Conclusion: Although certain LEPR haplotypes are more frequent in HELLP syndrome, we conclude that there is
no compelling evidence that the four studied LEPR SNP polymorphisms associated with the development of HELLP
syndrome.
Background
The human leptin receptor is a member of class 1 cyto-
kine receptor family, which was identified in the brain
[1]. The gene was assigned to chromosome 1. There are
six isoforms of the leptin receptor. The longest is the
most abundant in the hypothalamus, which is responsi-
ble for leptin signaling. The shortest isoform is predomi-
nant in peripheral tissues, and there is a soluble isoform
as well [2-6]. Leptin acts through the leptin receptor
(LEPR). Leptin circulates in free and in a leptin receptor
bound form. It acts via the receptors located in adipose
tissue, stomach, endometrium, liver, spleen, lungs, heart,
ovaries and placenta. Binding to the soluble receptor
might influence the amount of biologically available
ligand [2,7-9].
Leptin regulates the food intake and energy metabo-
lism, it was found that beside that, it stimulates the pro-
liferation of various cell types and it is considered to be
a new growth factor. It seems to have effect on
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tion of the blood pressure [10,11]. Leptin is a mitogenic
as well as pro-angiogenic factor in various cells [12].
Leptin acts synergistically with VEGF (vascular endothe-
lial growth factor) and fibroblast growth factor 2 (FGF-
2) to promote angiogenesis [13]. It has effect on the
expression of several genes involved in the angiogenesis
(MMP-2 and MMP-9) [14,15]. Leptin was implicated in
the pathogenesis of several disease including essential
hypertension and pre-eclampsia (PE) [16,17].
There are several studies showing higher expression of
the leptin gene in microarray experiments in PE and
HELLP syndrome [18-21]. As there are polymorphisms
which have effect on gene expression [22], and only one
study was dealing with two LEPR SNPs in PE [10].
However, the LEPR polymorphism has not been studied
in HELLP syndrome (hemolysis, elevated liver enzymes,
and low, platelet count), in the disease which is consid-
ered as a severe complication of PE. We decided to
determine the LEPR SNP polymorphism in HELLP syn-
drome and normal healthy subjects.
The determination of LEPR SNPs is mostly based on
PCR-RFLP, Mass Array genotyping and TaqMan deter-
minations in previous studies [22-26]. We introduced
first time the quantitative real-time PCR and melting
curve analysis method to determine those SNPs which
seemed to have functional relevance and suspected to
effect circulating leptin levels [10].
Methods
Between January 2003 and September 2008, 75 consecu-
tive Hungarian HELLP syndrome patients and 83 nor-
motensive healthy pregnant women were enrolled and
tested in the study for the leptin receptor SNP poly-
morphism at the 1
st Department of Obsterics and Gyne-
cology at the Semmelweis University Budapest,
Hungary. We determined the four SNPs in all samples.
The mean characteristics of the groups are shown in
Table 1. The healthy control patients were consecutively
selected from a group of normotensive, healthy pregnant
women, who were undergoing routine blood tests, and
were excluded if they developed hypertensive disorder.
In the case of HELLP syndrome cases the following
criteria were defined: hemolysis, classified by increased
lactic dehydrogenase activity (>600 IU/L); elevated liver
enzyme activity, defined as increased aspartate amino-
transferase and alanine aminotransferase levels (> 70
IU/L); and thrombocytopenia (≤ 100 platelets × 10
9/L)
[27]. IUGR was diagnosed in neonates when their birth
weight was below 10 percentile for gestational age by
weight based on Hungarian population tables.
The Ethical Committee of the Semmelweis University
has approved the study, all participants were informed
and they agreed in their involvement in the study and
they signed consent.
Three ml of peripheral blood was drawn from each
patient into an EDTA tube. Genomic DNA was
extracted from 0.2 ml samples by using the High Pure
PCR Template Isolation kit (Roche, Mannheim, Ger-
many), according to the manufacturer’s instructions
[28,29].
Four LEPR SNPs were determined by quantitative
real-time PCR and melting curve analyses on the Light-
Cycler instrument (Roche GmbH, Penzberg, Germany)
[rs1137100 (G+5193A; c.326A>G); rs1137101 (G
+27265A; c.668A>G); rs8179183 (G+44704C;
c.1968G>C); rs6413506 (A+71001G; c.3024A>G)]. Table
2 shows the primer and probe sequencies, they were
produced and designed by TibMolbiol (Berlin, Ger-
many). The PCR mix contained 1 μl of genomic DNA, 5
μM primers and probes, 1 μl of LightCycler FastStart
DNA Master HybProbe solution (Roche), and 4.5-5.0
mM MgCl2. PCR condition and melting curve reading
parameters were optimized. The annealing temperature
was 52-62°C.
The wild-type and the variant sequences showed dif-
ferent melting peaks, representing a distinguishable
melting point (Tm), while heterozygotes had both peaks
during the melting curve analysis.
The LEPR c.326A>G has the Tm 63°C for wild type
and 55°C for the variant (Figure 1). The LEPR c.668A>G
has the Tm 63°C for the wild type and 55°C for the var-
iant. The LEPR c.1968G>C has the Tm 63°C for the wild
type and 57°C for the variant. The LEPR c.3024A>G has
the Tm 47°C and 54°C for the variant.
Sample size estimation of the study was performed by
using Quanto 1.2.4 http://www.hydra.usc.edu statistical
program. Abate et al [30] published their data on
Lys109Arg LEPR polymorphism with a similar set up.
Our sample size provided sufficient statistical power
(>80% at Type I error rate of 0.05) to detect 21% differ-
ence in LEPR c.326A>G genotypes and 14% difference
in LEPR (AG AG GG AG) haplotypes between cases
and controls [31].
Statistical analyses were performed with the STATIS-
TICA software package (version 8; StatSoft, Inc., Tulsa,
Oklahoma, USA). The statistical significance of the dif-
ferences between patient groups was evaluated by
Mann-Whitney non-parametric U-test p < 0.05 was con-
sidered as statistically significant.
Pearson Chi-square (c
2)t e s tw a su s e df o rc o m p a r i n g
groups of categorical data (allele, genotype frequencies).
The haplotype analysis and control for deviation from
the Hardy-Weinberg equilibrium for the studied LEPR
polymorphisms was conducted using Haploview soft-
ware http://www.broad.mit.edu/mpg/haploview.
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quilibrium coefficient.
Results
PCR parameters were optimized for the four primer-
probe system to obtain easily recognizable Tm differ-
ences among the different alleles for detection of LEPR
SNPs (Figure 1). DNA samples of 83 healthy pregnant
and 75 HELLP syndrome patients were studied. There
was no statistically significant difference in the average
maternal age, the percentage of smokers and primiparas
between the HELLP and healthy pregnant control group
(Table 1).
Table 3 shows the allele distribution of the four SNPs.
There was no statistically significant difference in the
distribution of the alleles in the studied groups. The fre-
quency of the A allele was 77.0% in the HELLP syn-
drome group and 73.0% in the healthy pregnant
controls in the case of LEPR c.326A>G (K109). Our
sample size provided sufficient statistical power (>80%
at Type I error rate of 0.05) to detect 21% difference in
LEPR c.326A>G genotypes. The LEPR c.668A>G
(Q223R) showed 55.0% of the A allele in HELLP cases
compared to 58.0%. The frequency of the G allele was
80.0% in the HELLP patients and 84.0% in the healthy
controls in the case of LEPR c.668A>G (K656N). The
frequency of the A allele was 38.0% and 32.0% in the
LEPR c.3024A>G (S1008).
Table 3 shows the genotype frequencies of the four
SNPs. There was no significant difference in the distri-
bution of the genotypes in the study groups. However a
difference was observed in the frequency of the LEPR
c.326A>G AG genotype, which was almost twice as fre-
quent in HELLP syndrome, while it was not statistically
significant (40.0% vs. 24.0%; p = 0.089).
Table 4 shows the haplotype frequencies of the SNPs
in the study groups. We identified 24 haplotypes, how-
ever the (AG AG GG AG) was three times more fre-
quent in HELLP syndrome (4 vs. 12).
The Hardy-Weinberg equilibrium was observed for all
polymorphisms (Table 5).
The LDs of LEPR polymorphism at loci at c.326A>G/
c.668A>G/c.1968G>C/c.3024A>G are shown in Figure 2.
There were strong linkage disequilibrium (LD) between
loci c.326A>G and c.668A>G (D’ = 0.974), and
c.668A>G and c.1968G>C (D’ = 0.934), and c.326A>G
and c.1968G>C (D’ =0 . 8 8 5 ) ,a n dc.1968G>C and
Table 1 Clinical characteristics of the patients involved in the study
Normotensive healthy pregnants HELLP syndrome patients p value*
n=8 3 n=7 5
Average age (years) 31.76 ± 3.93 30.08 ± 5.12 ns
BMI before pregnancy (kg/m
2) 23.29 ± 3.88 25.99 ± 4.29 ns
Primipara 33 (40%) 43 (57%) ns
§
Systolic blood pressure (Hgmm) 121.8 ± 11.2 155.4 ± 19.4 0.0001
Diastolic blood pressure (Hgmm) 77.3 ± 7.9 97.8 ± 12.8 0.0001
Gestational age at delivery (week) 39.63 ± 1.87 31.2 ± 3.72 0.0001
Newborn’s weight (gramm) 3504.76 ± 426.2 1431.38 ± 700 0.0001
IUGR 0% 30 (40%) 0.0001
Smoking 6 (7%) 5 (7%) ns
A p value was calculated using the *Student’s t-test or
†Chi-Squared test.
Significant value was taken at the level of p < 0.05.
ns = non-significant.
Table 2 LEPR SNP primer and probe sequencies
LEPR
c.326A>G
Forward 5’-AgTggTACTCACTTTTCTAACTTATC-3’
Reverse 5’-gAATTAAAAAACATTgTTCAATACA-3’
Sensor 5’-AACATTgAAggAA(A/g)gACATTTgTT-Fluorescein
Anchor LC640-CAACAgTAAATTCTTTAgTTTTTCAACAAATAgg-
Phosphate
LEPR
c.668A>G
Forward 5’-CAgCCAAACTCAACgACACT-3’
Reverse 5’-CCACTCTTAATACCCCCAgTACTA-3’
Sensor 5’-CATTAgAggTgAC(T/C)ggAAAATTAC-Fluorescein
Anchor LC640-CCACCAgATgTgATTTTCAAACACATAAgg-
Phosphate
LEPR
c.1968G>C
Forward 5’-CAACTTgTCATTTTgCAgTTCCTA-3’
Reverse 5’-gCTTTCCgAAgATTAATAACAggAT-3’
Sensor 5’-TgACATTTTTCTC(C/g)TTTTTCATAgTATC-Fluorescein
Anchor LC640-CCATTAATTATTCTCCAAAATTCAggTCCT-
Phosphate
LEPR
c.3024A>G
Forward 5’-CCAgAgACAACCCTTTgTTAAATACg-3’
Reverse 5’-TggTgAAATTATgTTgggATgC-3’
Sensor 5’-gCACTTggTgAC(T/C)gAACTATTTAT-Fluorescein
Anchor LC640-gCCCTTgTTCTTCACCAgTTTCACTT-Phosphate
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with c.668A>G (D’ = 0.111) and c.326A>G (D’ = 0.398)
were weak.
Discussion
We determined four coding polymorphisms in LEPR
gene in HELLP syndrome patient by using quantitative
real-time PCR and melting curve analysis method, first
time according to our knowledge. The four LEPR SNPs
were LEPR c.326A>G, LEPR c.668A>G, LEPR
c.1968G>C and LEPR c.3024A>G.
We did not find significant difference in the fre-
quency of alleles, genotypes and haplotypes of the stu-
died LEPR SNPs’ in HELLP syndrome patients
compared to normotensive healthy pregnant controls.
Interesting finding was that in the case of LEPR
c.326A>G (K109) the AG genotype was present twice
more frequent in HELLP syndrome close to be statisti-
cally significant difference. The other is the frequency
of the (AG AG GG AG) haplotype which was three
times higher, but it was not statistically different due
to the low number of cases. We need more data to get
useful information on haplotypes as we had 24 in the
studied population. It would be interesting to involve
the fetal genotypes and haplotypes, but the present
ethical regulations do not permit it.
Our data is consistent with previous research in
patients who have PE, the observed allele frequencies
are similar to other published results in the Hungarian
population [10]. There are only a few publications on
the LEPR gene polymorphism in PE, according to our
knowledge it has not been studied in HELLP
Figure 1 Melting curve analysis of the LEPR G+5193A. The figure shows the melting curves of the LEPR G+5193A in wild type, a variant and
heterozygote sample. The melting point (Tm) of the wild type is 61°C and 55°C for the variant, the heterozygote sample has both peaks.
Table 3 Allele and genotype frequencies for the four polymorphisms of the LEPR gene
Allele
a Genotype
n1
b 2
b c
2 (P value) Odds ratio (95% CI) 11
b 12
b 22
b c
2 (P value)
LEPR c.326A>G
Control 83 38 (23%) 128 (77%) 0.6 (p = 0.437) 0.81 (0.49-1.36) 9 (11%) 20 (24%) 54 (65%) 4.83 (p = 0.089)
HELLP 75 40 (17%) 110 (73%) 5 (7%) 30 (40%) 40 (53%)
LEPR c.668A>G
Control 83 69 (42%) 97 (58%) 0.3 (p = 0.578) 0.88 (0.56-1.38) 18 (22%) 33 (40%) 32(38%) 0.48 (p = 0.785)
HELLP 75 67 (45%) 83 (55%) 17 (23%) 33 (44%) 25 (33%)
LEPR c.1968G>C
Control 83 140(84%) 26 (16%) 1.01 (p = 0.313) 0.74 (0.41-1.32) 59 (71%) 22 (27%) 2 (2%) 1.01 (p = 0.602)
HELLP 75 120 (80%) 30 (20%) 48(64%) 24 (32%) 3 (4%)
LEPR c.3024A>G
Control 83 113 (68%) 53 (32%) 1.28 (p = 0.258) 0.76 (0.48-1.2) 10 (12%) 33 (40%) 40 (48%) 3.66 (p = 0.16)
HELLP 75 93 (62%) 57 (38%) 8 (11%) 41 (54%) 26 (35%)
a Note. Allele 1 and 2 represent the first and second nucleotides given in the name of the SNP, respectively
b n(%)
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LEPR 223AA genotype in severely PE patients, which
S N Pi si n v o l v e di no u rs t u d ya l s o[ 1 0 ] .T h e ys t u d i e d
the LEPR A109G and LEPR A223G using PCR-RFLP
method. Based on our investigation there is no associa-
tion with the LEPR SNP polymorphism and the devel-
opment of HELLP syndrome. It is in agreement with
previous study on PE using two LEPR SNP polymorph-
isms on same size of cases and controls [10]. We
received similar allele and genotype frequencies on
these two SNPs. The presence of the 223G allele was
Table 4 Haplotype combination frequencies of the examined four polymorphisms in LEPR gene in HELLP patients and
normotensive healthy pregnant controls.
Haplotype combination Control HELLP
LEPR c.326A>G (K109) LEPR c.668A>G (Q223R) LEPR c.1968G>C (K656N) LEPR
c.3024A>G
(S1008)
n frequencies n frequencies
AA AA GG GG 16 0,19 10 0,13
AA AA CG AG 12 0,14 10 0,13
AA AG GG GG 12 0,14 6 0,08
AA AG CG AG 5 0,06 7 0,09
AG AG GG GG 5 0,06 3 0,04
AG AG GG AG 4 0,05 12 0,16
GG GG GG AA 4 0,05 2 0,03
GG GG GG AG 4 0,05 0 0,00
AG GG GG AG 3 0,04 5 0,07
AA GG GG GG 3 0,04 2 0,03
AG GG GG GG 2 0,02 4 0,05
AA AA CC AA 2 0,02 3 0,04
AG AG CG AG 2 0,02 3 0,04
AG AG CG AA 2 0,02 2 0,03
GG GG GG GG 1 0,01 2 0,03
AA AA GG AG 1 0,01 1 0,01
AA GG GG AG 1 0,01 0 0,00
AA AG GG AG 1 0,01 0 0,00
AA AG CG AA 1 0,01 0 0,00
AG AA GG GG 1 0,01 0 0,00
AG AG GG AA 1 0,01 0 0,00
AA AA CG AA 0 0,00 1 0,01
AG GG GG AA 0 0,00 1 0,01
GG GG CG AG 0 0,00 1 0,01
Table 5 The genotype frequencies of LEPR polymorphism
Allele frequency HW
LEPR SNP % tested Major Minor P-value
c. 326 A>G 100 A: 0.753 G: 0.247 0.06127
c. 668 A>G 100 A: 0.57 G: 0.43 0.06276
c. 1968 G>C 100 G: 0.823 C: 0.177 0.82495
c. 3024 A>G 100 G: 0.652 A: 0.348 0.68796
HW = Hardy-Weinberg equilibrium
lag out condition: 0.5 < Sample Missing, 0.1 < SNP Missing, 0.05 > SNP MAF,
0.05/4 = 0.0125 > SNP HWE p-value, with multiple correction
Figure 2 Haplotype analysis of the four studied SNPs.T h e r e
were strong linkage disequilibrium (LD) between loci c.326A>G and
c.6687A>G (D’ = 0.974), and c.668A>G and c.1968G>C (D’ = 0.934),
and c.326A>G and c.1968G>C (D’ = 0.885), and c.1968G>C and
c.3024A>G (D’ = 1.0).
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women [32]. Insulin resistance is considered as a risk
factor in PE.
Leptin receptors are widely expressed, showing that
leptin has effect on several function in the body. It has
an effect on angiogenesis and vascular disorders. Preli-
minary studies showed that platelets are the major
source of leptin receptor in the circulation. This sug-
gested that it could have effect on the development of
thrombosis [33].
Our real-time PCR and melting curve analysis method
is replacing the PCR-RFLP method which is widely used
for SNP determinations. We can reduce the number of
pipetting meanwhile reducing the risk of contamination
during the analysis of the samples. The melting curve
analysis makes the reliable allele determination as there
are 5-10°C differences in the melting points of the
alleles. The reaction is faster than the conventional PCR
and we can avoid the use of separate digesting, electro-
phoresis and detection step which is used during PCR-
RFLP. We can reach shorter detection times, less labor
and favorable price.
There is a lack of information on the role of LEPR and
its polymorphisms on the leptin levels in PE and HELLP
syndrome. We determined four coding LEPR but we did
not find correlation with the development of HELLP
syndrome. Further studies are needed to reveal the
molecular details of this association. We introduced the
quantitative real-time PCR combined with melting curve
analysis for the fast and reliable determination of the
LEPR SNPs.
Conclusion
Although certain LEPR haplotypes are more frequent in
HELLP syndrome, we conclude that there is no compel-
ling evidence that the four studied LEPR SNP poly-
morphisms associated with the development of HELLP
syndrome.
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